A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Biological: AZD5851 Sponsors: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Research | Study